ACTICCA-1 is an international multi centre trial, and is currently open in a few locations in the UK, and planned to open in 20+.
For more details, see:
Lead investigator on the ACTICCA-1 trial in the UK:
Professor John Bridgewater
Medical Oncologist, University College Hospital London
UCL Cancer Institute
72 Huntley Street
London WC1E 6AA
The BILCAP Study
Following the result of the long running BILCAP study, those who have undergone a resection for their cholangiocarcinoma or gall bladder cancer, and who fit the eligibility criteria, are now offered Capecitabine chemotherapy.
ACTICCA-1 is a randomized Phase III trial comparing Gemcitabine and Cisplatin against Capecitabine alone (standard treatment).
For more information on the BILCAP result, please see: https://ammf.org.uk/2017/05/18/bilcap-results-show-chemo-improves-survival And:https://ammf.org.uk/2017/06/09/the-bilcap-study-results/
In this video Dr John Marshall of Georgetown University, and Professor John Primrose of the University of Southampton, discuss the practice-changing findings of the BILCAP study which investigated adjuvant capecitabine for biliary tract cancer (cholangiocarcinoma). The pan-European study that Professor Primrose refers to (6:09 into the interview) is the ACTICCA-1 trial.